2022
DOI: 10.1016/j.bbih.2022.100555
|View full text |Cite
|
Sign up to set email alerts
|

Conserved YKL-40 changes in mice and humans after postoperative delirium

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
2

Relationship

5
0

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 47 publications
(66 reference statements)
1
3
0
Order By: Relevance
“…Our data are also compatible with the idea that blood–brain barrier dysfunction may simply be a marker of greater overall brain dysfunction after surgery, and that this greater overall brain dysfunction leads to delirium without a causal role for blood–brain barrier dysfunction itself. Nonetheless, our results are similar to results from mouse models of perioperative neurocognitive disorders, in which postoperative blood–brain barrier dysfunction has been demonstrated following orthopedic surgery and has been associated with delirium‐like behavioral changes 35–37 . Moreover, in these animal studies, delirium‐like behavioral changes are prevented when blood–brain barrier dysfunction is reduced by administration of netrin‐1, a protein that upregulates endothelial tight junction proteins to increase blood–brain barrier integrity 38 …”
Section: Discussionsupporting
confidence: 86%
See 1 more Smart Citation
“…Our data are also compatible with the idea that blood–brain barrier dysfunction may simply be a marker of greater overall brain dysfunction after surgery, and that this greater overall brain dysfunction leads to delirium without a causal role for blood–brain barrier dysfunction itself. Nonetheless, our results are similar to results from mouse models of perioperative neurocognitive disorders, in which postoperative blood–brain barrier dysfunction has been demonstrated following orthopedic surgery and has been associated with delirium‐like behavioral changes 35–37 . Moreover, in these animal studies, delirium‐like behavioral changes are prevented when blood–brain barrier dysfunction is reduced by administration of netrin‐1, a protein that upregulates endothelial tight junction proteins to increase blood–brain barrier integrity 38 …”
Section: Discussionsupporting
confidence: 86%
“…Nonetheless, our results are similar to results from mouse models of perioperative neurocognitive disorders, in which postoperative bloodbrain barrier dysfunction has been demonstrated following orthopedic surgery and has been associated with deliriumlike behavioral changes. [35][36][37] Moreover, in these animal studies, delirium-like behavioral changes are prevented when blood-brain barrier dysfunction is reduced by administration of netrin-1, a protein that upregulates endothelial tight junction proteins to increase blood-brain barrier integrity. 38 Two other lines of evidence also suggest that it is biologically plausible for blood-brain barrier dysfunction to play an etiologic role in delirium.…”
Section: Discussionmentioning
confidence: 99%
“…Fan Wang (MIT) and used as recently reported. 12 , 13 Briefly, Fos-TRAP2 transgenic mice (Fostm2.1[icre/ERT2]Luo/J) were crossed to Ai14 tdTomato reporter mice (B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato))Hze/J to obtain the double heterozygous (Fos-TRAP2; Ai14) mice used in the experiments described in this study (The Jackson Laboratory, Strains #030,323 and #007,914). In Fos-TRAP2; Ai14 double transgenic mice, neuronal activation and subsequent c-Fos induction results in the expression of CreER, which enters the nucleus in response to 4-hydroxytamoxifen (4-OHT) injection and causes recombination.…”
Section: Methodsmentioning
confidence: 99%
“…For example, leveraging clinical specimens and established biomarkers from wellphenotyped human cohorts can be combined with preclinical models to further clarify the role of specific biomarkers involved in delirium. 64 In addition, clinical studies may identify genetic predispositions to inform model creation and distinguish among mechanistic subtypes or mechanism-phenotype associations. When revealed, effective pharmacological treatments for delirium in humans or treatments that disrupt the delirium-neurodegeneration link present powerful opportunities for validating models that may ultimately have clinical benefit.…”
Section: Realistic Goals For Preclinical Modelsmentioning
confidence: 99%
“…Lastly, although current murine delirium models have illustrated moderate utility, improvement within the models requires further cross validation between clinical and preclinical research. For example, leveraging clinical specimens and established biomarkers from well‐phenotyped human cohorts can be combined with preclinical models to further clarify the role of specific biomarkers involved in delirium 64 . In addition, clinical studies may identify genetic predispositions to inform model creation and distinguish among mechanistic subtypes or mechanism‐phenotype associations.…”
Section: Introductionmentioning
confidence: 99%